SCHEMBL4916124

SCHEMBL4916124

CCOc1nccnc1-c1cc(C2CC[N]2)on1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 11/20 0.33
HCRTR2 O43614 2/20 0.33
S1PR1 P21453 1/20 0.33
HCRTR1 O43613 1/20 0.33
CYP1A2 P05177 1/20 0.32
HCK P08631 1/20 0.32
FGR P09769 1/20 0.32
RPS6KB1 P23443 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
MAP2K2 P36507 1/20 0.32
MAP2K1 Q02750 1/20 0.32
RPS6KA1 Q15418 1/20 0.32
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
KMT2A Q03164 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3928074 0.91 HCRTR2 (0.33) HCRTR2S1PR1HCRTR1
SCHEMBL4913991 0.87 RET (0.34) RETHCRTR2HCRTR1CYP1A2HCK
SCHEMBL4917757 0.84 RET (0.34) RETCYP1A2HCKFGRRPS6KB1
SCHEMBL4916841 0.81 CHRNB2 (0.33) RETHCRTR2S1PR1HCRTR1
SCHEMBL4913152 0.81 CHRNB2 (0.33) RETHCRTR2S1PR1HCRTR1
SCHEMBL4912257 0.80 RET (0.36) RETCYP1A2HCKFGRRPS6KB1
SCHEMBL3917360 0.78 CHRNB2 (0.38) RETHCRTR2HCRTR1
SCHEMBL3917354 0.78 CHRNB2 (0.38) RETHCRTR2HCRTR1
SCHEMBL4917615 0.77 RET (0.34) RETCYP1A2HCKFGRRPS6KB1
SCHEMBL4640974 0.74 RET (0.32) RETCYP1A2HCKFGRRPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161278-A1 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity ASTRAZENECA AB (SE) 2008-07-03 US disclosed
EP-1863797-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006100461-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161278-A1 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity IGF1R, IGFBP1, IGFBP2 RET 266/4885HCRTR2 3688/4885S1PR1 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.